{"entity":{"id":"pharmamar","kind":"company","name":"PharmaMar","aka":[],"tldr":"Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin.","summary":"PharmaMar, based in Madrid and listed as PHM.MC, is the Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin. It discovered lurbinectedin, sold as Zepzelca and partnered with Jazz in the United States, and trabectedin, sold as Yondelis, and the success of the IMforte trial in 2025 broadened lurbinectedin from relapsed small-cell lung cancer into first-line maintenance. OnCo links it to small-cell lung cancer, Ewing sarcoma and soft tissue sarcomas, and to the lurbinectedin drug record. Whether marine-derived transcription inhibitors can find further indications, or whether lurbinectedin remains its last major product, is the open question. Lurbinectedin has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://pharmamar.com"}],"tags":[],"related":[],"cancers":["sclc","sarcoma"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["lurbinectedin","plitidepsin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07644039","nct06088290"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Madrid","country":"ES","companyType":"biotech","website":"https://pharmamar.com","ticker":"PHM.MC","investors":[],"funding":[]},"route":"/companies/pharmamar/","neighbours":{"cancer":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"},{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/"}],"trial":[{"id":"nct00229203","kind":"trial","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","route":"/trials/nct00229203/"},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/"},{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/"},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/"},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/"},{"id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/"},{"id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/"}]}}